MX2021010135A - Usos terapeuticos de relacorilante, un modulador del receptor de glucocorticoides de azadecalina fusionada con heteroaril-cetona. - Google Patents
Usos terapeuticos de relacorilante, un modulador del receptor de glucocorticoides de azadecalina fusionada con heteroaril-cetona.Info
- Publication number
- MX2021010135A MX2021010135A MX2021010135A MX2021010135A MX2021010135A MX 2021010135 A MX2021010135 A MX 2021010135A MX 2021010135 A MX2021010135 A MX 2021010135A MX 2021010135 A MX2021010135 A MX 2021010135A MX 2021010135 A MX2021010135 A MX 2021010135A
- Authority
- MX
- Mexico
- Prior art keywords
- disorder
- relacorilant
- grm
- heteroaryl
- fused azadecalin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen métodos y composiciones para diagnosticar a un paciente sospechoso de padecer de, y para tratar un paciente que padece de, un trastorno tal como hipercortisolemia, síndrome metabólico, pre-diabetes, diabetes, síndrome de Cushing, enfermedad de Cushing, hiperglicemia secundaria a hipercortisolemia, una enfermedad hepática, un trastorno cardiaco, presión arterial alta, un trastorno de la coagulación sanguínea, un cáncer, un trastorno psicológico, aumento de peso, un trastorno de control de glucosa, un trastorno óseo (por ejemplo, osteoporosis), hipogonadismo, pseudoacromegalia, tumores hipofisarios, hipercortisolismo funcional, Tumores Secretores de ACTH, neuropatía periférica, dislipidemia y otros trastornos. Los métodos y composiciones incluyen la administración de un modulador del receptor de glucocorticoides de azadecalina fusionada con heteroaril-cetona (GRM). El GRM de azadecalina fusionada con heteroaril-cetona preferido es ((R)-(1-(4-fluorofeni l)-6-((1-metil-1H-pirazol-4-il)sulfonil)-4,4a,5,6,7,8-hexahidro-1 H-pirazolo[3,4-g]isoquinolin-4a-il)(4-(trifluorometil)piridin-2-i l)metanona) relacorilante. En algunos casos, el GRM (por ejemplo, relacorilante) se administra oralmente. En algunos casos, el GRM (por ejemplo, relacorilante) se administra oralmente sin comida.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962809327P | 2019-02-22 | 2019-02-22 | |
US201962814441P | 2019-03-06 | 2019-03-06 | |
US201962833517P | 2019-04-12 | 2019-04-12 | |
PCT/US2020/019167 WO2020172501A1 (en) | 2019-02-22 | 2020-02-21 | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021010135A true MX2021010135A (es) | 2021-09-23 |
Family
ID=72141382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021010135A MX2021010135A (es) | 2019-02-22 | 2020-02-21 | Usos terapeuticos de relacorilante, un modulador del receptor de glucocorticoides de azadecalina fusionada con heteroaril-cetona. |
Country Status (14)
Country | Link |
---|---|
US (4) | US11058670B2 (es) |
EP (1) | EP3927345A4 (es) |
JP (2) | JP2022523376A (es) |
KR (1) | KR20210118971A (es) |
CN (1) | CN113490496A (es) |
AU (1) | AU2020226863B2 (es) |
BR (1) | BR112021015129A2 (es) |
CA (1) | CA3131263C (es) |
CL (1) | CL2021002145A1 (es) |
IL (1) | IL285771A (es) |
MX (1) | MX2021010135A (es) |
SG (1) | SG11202108964YA (es) |
WO (1) | WO2020172501A1 (es) |
ZA (1) | ZA202105633B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
JP7218438B2 (ja) | 2018-12-19 | 2023-02-06 | コーセプト セラピューティクス, インコーポレイテッド | レラコリラント含有医薬製剤、ヘテロアリールケトン縮合アザデカリン化合物 |
KR20210095939A (ko) * | 2018-12-21 | 2021-08-03 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 글루코코르티코이드 수용체 조절제의 투여에 의한 쿠싱 증후군의 과응고병증의 치료 |
SG11202108964YA (en) | 2019-02-22 | 2021-09-29 | Corcept Therapeutics Inc | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
EP4157274A4 (en) * | 2020-05-27 | 2024-06-12 | Corcept Therapeutics Incorporated | CONCURRENT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACTORILANTS AND CYP2C9 SUBSTRATES |
WO2022134033A1 (en) * | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
WO2022166810A1 (zh) * | 2021-02-03 | 2022-08-11 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
WO2023225282A1 (en) * | 2022-05-20 | 2023-11-23 | Corcept Therapeutics Incorporated | Methods of treating cushing's syndrome and liver disorders, and of reducing liver toxicity of other drugs administered to a patient |
WO2024077169A1 (en) * | 2022-10-06 | 2024-04-11 | Corcept Therapeutics Incorporated | Formulations of glucocorticoid receptor modulators |
WO2024118735A1 (en) * | 2022-11-30 | 2024-06-06 | Corcept Therapeutics Incorporated | Treatments for cushing's syndrome that do not significantly affect cardiac rhythms |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS322220B1 (es) | 1954-11-30 | 1957-04-11 | ||
CA1270488A (en) | 1983-09-26 | 1990-06-19 | John M. Schaus | Pyrazole-ring alkylated pyrazoloquinolines and intermediates |
GB8828669D0 (en) | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
JP3160941B2 (ja) | 1991-06-17 | 2001-04-25 | 東レ株式会社 | カルバゾール誘導体および免疫抑制剤 |
FR2697252B1 (fr) | 1992-10-28 | 1994-12-09 | Fournier Ind & Sante | Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique. |
ES2173921T3 (es) | 1993-08-06 | 2002-11-01 | Glaxosmithkline Spa | Derivados de hidroisoquinolina. |
US5693646A (en) | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
EP1061919A4 (en) | 1998-03-10 | 2002-09-04 | Res Triangle Inst | NEW OPIATES, METHOD FOR THE PRODUCTION AND USE THEREOF |
GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
US6583180B2 (en) | 2001-02-14 | 2003-06-24 | Abbott Laboratories | Glucocorticoid receptor modulators |
US20020115613A1 (en) | 2001-02-16 | 2002-08-22 | Kumar M. Vijay | Treatment of prostate cancer |
AU2002355929A1 (en) | 2001-07-17 | 2003-03-03 | Smithkline Beecham Corporation | Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
MXPA04000692A (es) | 2001-07-23 | 2004-04-21 | Corcept Therapeutics Inc | MeTODOS PARA EVITAR GANANCIA DE PESO INDUCIDA ANTISICOTICA. |
AU2003214879B2 (en) | 2002-01-22 | 2008-02-07 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
WO2004004653A2 (en) | 2002-07-02 | 2004-01-15 | Corcept Therapeutics, Inc. | Methods for treating psychosis associated with interferon-alpha therapy |
TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
EP1660081A1 (en) | 2003-09-03 | 2006-05-31 | Wyeth | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same |
CA2552419C (en) | 2004-01-09 | 2013-04-23 | Corcept Therapeutics, Inc. | Azadecalin glucocorticoid receptor modulators |
EP1723174A1 (en) | 2004-02-26 | 2006-11-22 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health | A novel modulator of glucocorticoid receptor activities |
NZ550362A (en) | 2004-03-09 | 2010-06-25 | Corcept Therapeutics Inc | Fused ring azadecalin glucocorticoid receptor modulators |
AU2006232660B2 (en) * | 2005-04-05 | 2010-03-25 | F. Hoffmann-La Roche Ag | 1H-Pyrazole 4-Carboxylamides, their preparation and their use as 11Beta-hydroxysteroid dehydrogenase |
NZ561609A (en) | 2005-05-12 | 2010-03-26 | Abbott Lab | 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters |
US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
US7640389B2 (en) | 2006-02-28 | 2009-12-29 | Freescale Semiconductor, Inc. | Non-volatile memory having a multiple block erase mode and method therefor |
EP1932843A1 (en) | 2006-12-14 | 2008-06-18 | sanofi-aventis | Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals |
ES2448839T3 (es) | 2007-11-01 | 2014-03-17 | Bristol-Myers Squibb Company | Compuestos no esteroideos útiles como moderadores de la actividad del receptor de glucocorticoides AP-1 y/o NF-kappa b y uso de los mismos |
SG185952A1 (en) | 2007-11-12 | 2012-12-28 | Bipar Sciences Inc | Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
US20120022121A1 (en) | 2007-11-29 | 2012-01-26 | Dalton James T | Indoles, derivatives and analogs thereof and uses therefor |
US20090156672A1 (en) | 2007-12-17 | 2009-06-18 | Northwestern University | Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities |
WO2009155481A1 (en) | 2008-06-20 | 2009-12-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
US20100135956A1 (en) | 2008-11-21 | 2010-06-03 | Auspex Pharmaceuticals, Inc. | Steroid modulators of progesterone receptor and/or glucocorticoid receptor |
US8461172B2 (en) | 2009-05-12 | 2013-06-11 | Corcept Therapeutics, Inc. | Solid forms and process for preparing |
US8710035B2 (en) | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
KR20130106378A (ko) | 2010-08-27 | 2013-09-27 | 코어셉트 쎄라퓨틱스, 잉크. | 피리딜-아민 융합된 아자데칼린 조절제 |
US9314473B2 (en) | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
PL3329919T3 (pl) | 2011-11-11 | 2020-05-18 | Gilead Apollo, Llc | Inhibitory ACC i ich zastosowania |
US9289436B2 (en) | 2012-02-24 | 2016-03-22 | The University Of Chicago | Method of treatment of prostate cancer with androgen receptor and glucocorticoid receptor antagonists |
WO2013130420A1 (en) | 2012-02-27 | 2013-09-06 | Corcept Therapeutics, Inc. | Phenyl heterocycloalkyl glucocorticoid receptor modulators |
ES2930298T3 (es) * | 2012-05-25 | 2022-12-09 | Corcept Therapeutics Inc | Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona |
US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
PT2861611T (pt) | 2012-05-25 | 2016-10-11 | Janssen Sciences Ireland Uc | Nucleósidos de espirooxetano de uracilo |
ES2869172T3 (es) * | 2013-11-25 | 2021-10-25 | Corcept Therapeutics Inc | Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro |
WO2016140867A1 (en) | 2015-03-02 | 2016-09-09 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors |
KR20180052120A (ko) | 2015-08-13 | 2018-05-17 | 코어셉트 쎄라퓨틱스, 잉크. | Acth-의존성 쿠싱 증후군을 감별 진단하는 방법 |
BR112018067330A2 (pt) | 2016-03-01 | 2019-01-22 | Corcept Therapeutics Inc | método para o tratamento de paciente com carga tumoral |
US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
US10413540B2 (en) | 2017-03-31 | 2019-09-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
US20180325891A1 (en) * | 2017-05-10 | 2018-11-15 | Corcept Therapeutics, Inc. | Octahydro azadecalin formulations |
KR20210095939A (ko) * | 2018-12-21 | 2021-08-03 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 글루코코르티코이드 수용체 조절제의 투여에 의한 쿠싱 증후군의 과응고병증의 치료 |
SG11202108964YA (en) | 2019-02-22 | 2021-09-29 | Corcept Therapeutics Inc | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
-
2020
- 2020-02-21 SG SG11202108964YA patent/SG11202108964YA/en unknown
- 2020-02-21 US US16/797,421 patent/US11058670B2/en active Active
- 2020-02-21 WO PCT/US2020/019167 patent/WO2020172501A1/en unknown
- 2020-02-21 KR KR1020217030352A patent/KR20210118971A/ko not_active Application Discontinuation
- 2020-02-21 AU AU2020226863A patent/AU2020226863B2/en active Active
- 2020-02-21 BR BR112021015129-0A patent/BR112021015129A2/pt unknown
- 2020-02-21 CN CN202080015826.9A patent/CN113490496A/zh active Pending
- 2020-02-21 JP JP2021549571A patent/JP2022523376A/ja active Pending
- 2020-02-21 EP EP20759882.2A patent/EP3927345A4/en active Pending
- 2020-02-21 CA CA3131263A patent/CA3131263C/en active Active
- 2020-02-21 MX MX2021010135A patent/MX2021010135A/es unknown
-
2021
- 2021-06-09 US US17/343,524 patent/US11590113B2/en active Active
- 2021-08-10 ZA ZA2021/05633A patent/ZA202105633B/en unknown
- 2021-08-13 CL CL2021002145A patent/CL2021002145A1/es unknown
- 2021-08-22 IL IL285771A patent/IL285771A/en unknown
-
2022
- 2022-12-20 US US18/084,866 patent/US11684612B2/en active Active
-
2023
- 2023-05-09 US US18/144,979 patent/US12097192B2/en active Active
- 2023-10-12 JP JP2023176874A patent/JP2024009951A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US12097192B2 (en) | 2024-09-24 |
US20230131372A1 (en) | 2023-04-27 |
JP2022523376A (ja) | 2022-04-22 |
CA3131263A1 (en) | 2020-08-27 |
KR20210118971A (ko) | 2021-10-01 |
SG11202108964YA (en) | 2021-09-29 |
US20230346756A1 (en) | 2023-11-02 |
WO2020172501A1 (en) | 2020-08-27 |
JP2024009951A (ja) | 2024-01-23 |
US20210338643A1 (en) | 2021-11-04 |
US11684612B2 (en) | 2023-06-27 |
ZA202105633B (en) | 2023-02-22 |
US20200268723A1 (en) | 2020-08-27 |
AU2020226863A1 (en) | 2021-08-12 |
CL2021002145A1 (es) | 2022-01-28 |
CN113490496A (zh) | 2021-10-08 |
CA3131263C (en) | 2024-01-02 |
EP3927345A1 (en) | 2021-12-29 |
EP3927345A4 (en) | 2022-12-21 |
US11590113B2 (en) | 2023-02-28 |
US11058670B2 (en) | 2021-07-13 |
BR112021015129A2 (pt) | 2021-09-28 |
AU2020226863B2 (en) | 2023-04-06 |
IL285771A (en) | 2021-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021010135A (es) | Usos terapeuticos de relacorilante, un modulador del receptor de glucocorticoides de azadecalina fusionada con heteroaril-cetona. | |
CN101980708B (zh) | 作为vegf驱动的血管生成过程的有效调节剂的咪唑并喹啉类及嘧啶衍生物 | |
EA018839B1 (ru) | Замещенные производные 2,3-дигидроимидазо[1,2-с]хиназолина, полезные для лечения гиперпролиферативных нарушений и болезней, связанных с ангиогенезом | |
US8470811B2 (en) | Substituted heterocyclylbenzylpyrazoles and use thereof | |
EA027476B1 (ru) | Применение n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида для лечения кастрационно-резистентного рака простаты и остеобластических метастазов в кости | |
US20150328188A1 (en) | Combination Therapies for the Treatment of Proliferative Disorders | |
WO2010054764A1 (de) | Heteroaromatische verbindungen zur verwendung als hif-inhibitoren | |
UA128348C2 (uk) | Сполуки для лікування кіназозалежних розладів | |
CN115667255A (zh) | 卤代杂芳基和其他杂环激酶抑制剂及其用途 | |
CN107530304A (zh) | Olig2活性的抑制 | |
CN108586443B (zh) | 一种防治支气管肺癌的药物及其制备方法 | |
CN102834100A (zh) | 新型pan-CDK抑制剂用于治疗肿瘤的用途 | |
US20090048292A1 (en) | Synergistic combination | |
KR102102109B1 (ko) | N-벤즈히드릴 퀴뉴클리딘 유도체를 포함하는 나트륨 누출 채널 억제용 조성물 | |
CN108349900A (zh) | 雄激素受体拮抗剂 | |
JP6746794B2 (ja) | 重水素化3−(4,5−置換アミノピリミジン)フェニル誘導体及びその使用 | |
CN110087653A (zh) | 用于治疗肺高血压的组合疗法 | |
DK2914264T3 (en) | 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE FOR USE FOR THE TREATMENT OF HEPATOCELLULAR CARCINOM (HCC) | |
KR20100021444A (ko) | 플루오로퀴놀론을 사용하여 염증을 조절하기 위한 조성물 및 방법 | |
US9980966B2 (en) | Combinations of cancer therapeutics | |
US20240024324A1 (en) | Kinase inhibitor combinations for cancer treatment | |
Allison et al. | Comparison of the in vivo hemodynamic effects of the antiarrhythmic agents vernakalant and flecainide in a rat hindlimb perfusion model | |
AU2021256476A1 (en) | Benzimidazole compound for the treatment of metabolic disorders |